In
June 2013, EMBL and EMBL-EBI have joined Global Alliance, an
organization that partners with different healthcare providers and
research institutes which will share their findings, databases and
product description among other Global Alliance partners for further
comments and refinement. Such collaboration and alliances enable
various research organizations and institutes for developing
interoperable information-technology platforms for biomedicine for
novel and low cost drug developments and detecting the root cause for
some of the incurable diseases such as Alzheimer’s disease and
other similar diseases. Major drivers that are compelling the growth
for Bioinformatics in IVD Testing Market include collaboration of
bioinformatics and in-vitro diagnostic companies with information
technology companies for designing and developing specific software
and algorithms which can be practically implemented in detecting and
diagnosing specific un-curable or inherited diseases.
Obtain
the Future Market Analysis for Bioinformatics in IVD Testing at:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2439
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2439
Traditionally
in-vitro diagnostic tests earlier were generally performed and
interpreted by clinical and lab technicians but with the growing
prevalence of rare and life threatening diseases such as HIV, cancer
among others have created a huge market for DNA sequencing, mass
spectroscopy, genomics and proteomics based technology and devices.
Many IT giants such as IBM and others are collaborating with
laboratory testing vendors and manufacturers for developing
specialized algorithms and software pertaining to specific disease or
conditions which in near future would complement the skills of human
based test interpretations and diagnosis. Research efforts in last
two decades have provided us huge amount of genomic information for
almost each and every form of life. Bioinformatics is a
multidisciplinary research field that combines computer science,
biology, statistics and mathematics for the management of biological
information. The software and applications used in bioinformatics is
used to gather, analyze, store and integrate genetic and biological
information which can later be applied to gene based drug
developments. Computer diagnostics offers wide opportunities to
clinicians and pathologists in detecting difficult to culture
pathogenic bacteria and viruses to reveal epidemiology and disease
prevalence. Bioinformatics based testing have made a major impact and
contribution in uplifting cancer diagnostics and therapeutic
management.
One
of the novel technological innovation in this field comprises IBM’s
Watson supercomputer which uses specific algorithms and previously
stored patient databases in analyzing and recommending the best
suitable treatment and therapy on a case to case basis. Such
technological up gradations have not only let researchers and
scientists in disease analysis but also divulged insight to questions
as to why a person gets affected by certain diseases such as cancers
or tumors and difference in therapeutic responses from one person to
other.
The
reduced cost of genome sequencing in past few years is fueling the
flow of information with respect to genetic basis of health and
diseases. Lack of norms and government interventions for sharing and
protecting data of patients are one of the prominent reasons for slow
uptake of genomic medicines in clinical setting. Lack of awareness
about biobanks and other similar depositories which stores and
protect patient history and records also a major restraint for
bioinformatics based IVD testing market. The global market for
bioinformatics in IVD testing can be segmented on the basis of test
types such as blood based tests and tissue based tests. Apart from
this they can also be further segmented on the basis of disease type
and recent trends with respect to bioinformatics based test such as
mass spectroscopy based test, genome sequencing tests as well as
prominent software types.
No comments:
Post a Comment